Cambridge University's dominance in biotechnology, as per QS rankings, arises from its interdisciplinary Bio21 Institute and collaborations with AstraZeneca, yielding breakthroughs in gene editing and regenerative medicine. The "Silicon Fen" cluster, with 470+ biotech firms contributing £2.9 billion annually, fosters spin-outs and global partnerships, making it Europe's biotech epicenter through world-class labs and a talent pipeline from elite programs.